Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

drisapersen

- PMLiVE

Japanese product news in brief

Home launch for Astellas' Xtandi, GSK files COPD drug for approval and more

- PMLiVE

European prescribing of new anticoagulants on the increase

Daiichi Sankyo-backed study shows doctors are turning to new drugs for VTE

- PMLiVE

Santhera closer to filing for muscular dystrophy drug

Catena/Raxone slows loss of lung function in late stage trial

Biomarin

EC approves Biomarin rare genetic disorder drug

Vimizim now available to treat Morquio A syndrome

- PMLiVE

Sun Pharma offers $4bn for Ranbaxy

Follows period of manufacturing problems at Daiichi-owned Indian generics company

- PMLiVE

More woes for Daiichi as Ranbaxy units stop API shipments

Manufacturing problems continue to gather pace

- PMLiVE

FDA backs BioMarin drug for rare enzyme disorder

Vimizim is first drug approved in US under rare paediatric disease priority review

- PMLiVE

CHMP turns down drugs for MS, cancer and muscular dystrophy

Negative EU recommendations for Teva, AB Science and PTC Therapeutics

- PMLiVE

Another Ranbaxy plant falls foul of FDA

Indian company violates Good Manufacturing Practice

- PMLiVE

GSK ends muscular dystrophy deal

Terminates rare disease collaboration with Prosensa after trial disappointment

Daiichi Sankyo logo

Daiichi files new anticoagulant edoxaban in US and EU

Seeks approvals in atrial fibrillation and venous thromboembolism

Daiichi Sankyo logo

Daiichi Sankyo says meets targets in AF study

Edoxaban on course to add to next generation anticoagulants to replace warfarin

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links